A Phase 3 interventional study of Irbesartan and Placebo in Atrial Fibrillation, sponsored by Bristol-Myers Squibb. Completed at 3 sites in Spain. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2010-02-17.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
The main purpose of the study is to compare the mean AERP between treatment groups based on the hypothesis that in subjects with paroxysmal AF, Irbesartan prevents electrophysiological remodeling resulting in a prolonged atrial effective refractory period relative (AERP) to placebo.
3,870 studies on the registry are indexed under Atrial Fibrillation; 924 are open to participants now.
This study's planned enrollment of 44 is below the median of 144 across 2,380 interventional studies indexed under Atrial Fibrillation.
Browse Atrial Fibrillation studies →Bristol-Myers Squibb is the lead sponsor of 1,538 studies on the registry; 116 are open to participants now.
Of its 429 completed or terminated interventional studies of FDA-regulated products, 223 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Irbesartan
Drug: Placebo
Tablets, Oral, 300 mg, once daily, 30 days.
Also known as: Avapro
Tablets, Oral, 0 mg, once daily, 30 days.
Irbesartan effect on duration of Atrial Effective Refractory Period (AERP) in paroxysmal AF (PAF) patients.
Time frame: The measures are taken after 31 days of irbesartan treatment
Irbesartan effect on A Function RP
Time frame: The measures are taken after 31 days of irbesartan treatment
Irbesartan effect on atrial conduction intervals after basal & extra-stimuli, in PAF patients
Time frame: The measures are taken after 31 days of irbesartan treatment
Refractoriness dispersion
Time frame: The measures are taken after 31 days of irbesartan treatment
This study is completed, as verified in Jun 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bristol-Myers Squibb